Tagraxofusp
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tagraxofusp: From CD4+/CD56+ Hematodermic Neoplasm to Esotropia
One-Sentence Summary
Tagraxofusp was originally used to treat CD4+/CD56+ hematodermic neoplasm (blastic plasmacytoid dendritic cell neoplasm). The TxGNN model predicts it may be effective for esotropia, but there are currently 0 clinical trials and 0 publications supporting this prediction. This is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | CD4+/CD56+ hematodermic neoplasm |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of BLAs/NDAs | 1 (BLA761116, Elzonris, cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacological knowledge, tagraxofusp is a CD123-directed cytotoxin (interleukin-3 fused to a truncated diphtheria toxin). It kills CD123-expressing hematologic cells, which explains its activity in CD4+/CD56+ hematodermic neoplasm.
Esotropia is an ocular motility disorder (inward eye deviation) with no known CD123-driven pathology. No plausible mechanistic link between the original indication and esotropia was identified. The high TxGNN score (99.73%) is a statistical output of the knowledge-graph model and is not backed by clinical or literature evidence.
The drug’s systemic toxicity, including capillary leak syndrome and hepatotoxicity, also argues against use in a non-malignant condition such as esotropia.
Other top-ranked predictions show the same pattern. They include pre-malignant neoplasm, inner ear neoplasm, benign neoplasm of tongue, bronchial adenomas/carcinoids (childhood), chondroid hamartoma, non-seminomatous lesion, ductal or ductular proliferation, cystic neoplasm, and thyroglossal duct cyst. All have scores of about 99.7%, all are Evidence Level L5, and none has supporting trials or publications. The only indirect rationale is for pre-malignant neoplasm, where some pre-malignant hematologic conditions (e.g., myelodysplastic syndromes) express CD123. That category is too non-specific to act on.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761116 | Elzonris (Stemline Therapeutics, Inc.) | Injection, solution | Not listed (status: cancelled) |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (CD123-directed cytotoxic fusion protein) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Liver function and general haematological and clinical monitoring; capillary leak syndrome monitoring (known risk for this drug class) |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 66 interactions were identified in the data compiled for this report. All 20 shown are of Moderate severity, and most involve antidiabetic agents: acarbose, albiglutide, alogliptin, metformin, pioglitazone, canagliflozin, chlorpropamide, dapagliflozin, saxagliptin, dulaglutide, empagliflozin, linagliptin, glimepiride, semaglutide, and several insulins (aspart, degludec, detemir, glargine, glulisine, human isophane).
- Known toxicity concerns: Capillary leak syndrome and hepatotoxicity have been noted in the mechanistic assessment for this drug. They are not drawn from label text.
For full warnings and contraindications, please refer to the package insert, as this information was not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials, no publications, and no plausible mechanistic link between a CD123-directed cytotoxin and esotropia. The drug’s systemic toxicity makes the risk-benefit balance unfavorable for a non-malignant condition. In addition, the only US license is cancelled.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data (MOA)
- Preclinical or mechanistic evidence that links CD123 or IL-3 receptor biology to esotropia
- A clearer, better-defined indication from the lower-ranked list (for example, specific CD123+ pre-malignant hematologic conditions) if the evaluation is to continue
- Confirmation of current US market and supply status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.